Open Access
MicroRNA and ALK-positive anaplastic large cell lymphoma
Coralie Hoareau-Aveilla1,2,3,Olaf Merkel4,5,Fabienne Meggetto1,2,3,4,*
Inserm, UMR1037 CRCT, F-31000 Toulouse, France
Universite Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
CNRS, ERL5294 CRCT, F-31000 Toulouse, France
European Research Initiative on ALK-related malignancies (ERIA)
Institute of Clinical Pathology, Medical University Vienna, 1090 Vienna, Austria
DOI: 10.2741/S435 Volume 7 Issue 2, pp.217-225
Published: 01 June 2015
(This article belongs to the Special Issue ALK: 20 years of discoveries)
*Corresponding Author(s):  
Fabienne Meggetto

In this review we describe the current literature covering the role of microRNA in anaplastic large cell lymphoma (ALCL). MicroRNA is one of the best characterized subgroups of non-coding RNAs and it is now becoming clear that its importance in oncogenesis has been greatly underestimated. In ALCL the deregulation of a diverse range of microRNA has been demonstrated however much less is known about the physiological consequences of this deregulation. Here we focus on the subgroup of ALCL bearing the anaplastic lymphoma kinase (ALK) translocation (ALK+). The pathways linking oncogenic ALK signaling and the regulation of microRNA are now becoming established with the transcription factor STAT3 appearing to play an important role in the epigenetic regulation. This review will discuss our current understanding of the role of microRNAs in ALK-mediated oncogenesis and will explain why we believe these new findings suggest that the use of methyltransferase inhibitors together with microRNA-specific drugs could be a useful addition to our current armamentarium in the fight against ALK(+) ALCL.

Key words

ALK+ ALCL, microRNA, STAT3, Review

Share and Cite
Coralie Hoareau-Aveilla, Olaf Merkel, Fabienne Meggetto. MicroRNA and ALK-positive anaplastic large cell lymphoma. Frontiers in Bioscience-Scholar. 2015. 7(2); 217-225.